Abstract: A rotary positioning adjustment device includes a shaft sleeve and a connecting rod. A reel is fixedly connected with an end of the connecting rod; a fixed seat is sleeved on the connecting rod; the reel is arranged in the fixed seat; and a power storage assembly is installed in the shaft sleeve. The power storage assembly includes a power input piece, a second torsion spring and a power output piece; a first support leg of the second torsion spring is connected in a hooked mode with one side of an input block of the power input piece, and a second support leg of the second torsion spring is connected in a hooked mode with the other side of the input block. A curtain includes the rotary positioning adjustment device.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Systems and methods to implement a USB and Thunderbolt optical signal transceiver are described. One method includes detecting presence of a USB sideband signal received over an optical communication channel and associated with a USB communication request. Responsive to the detecting, the method may determine that the USB communication request corresponds to a USB communication mode and perform a sideband negotiation. The USB communication mode may be enabled. A specified number of channels associated with the USB communication request may be determined. USB communication may be performed using the specified number of channels over the optical communication channel in the USB communication mode.

Abstract: Systems and methods to implement a USB and Thunderbolt optical signal transceiver are described. One method includes detecting presence of a USB sideband signal received over an optical communication channel and associated with a USB communication request. Responsive to the detecting, the method may determine that the USB communication request corresponds to a USB communication mode and perform a sideband negotiation. The USB communication mode may be enabled. A specified number of channels associated with the USB communication request may be determined. USB communication may be performed using the specified number of channels over the optical communication channel in the USB communication mode.

Abstract: Systems and methods for HDMI signal communication over an optical communication link are described. One aspect includes receiving an HDMI control signal from an HDMI master device, and another HDMI control signal from an HDMI sink terminal via a communication resources. The method identifies half-duplex communication resource contention between the HDMI control signal and the other HDMI control signal, and transitions a communication direction of the half-duplex communication resources to give the HDMI control signal precedence over the other HDMI control signal. Subsequent to transitioning the communication direction, the method transfers the HDMI control signal to the HDMI sink terminal via the communication resources. Subsequent to transferring the HDMI control signal, the method again transitions the direction of the half-duplex communication resources, and transfers the other HDMI control signal to the HDMI master device.

Abstract: Systems and methods to transmit audio-video signals over an optical communication channel are described. One aspect includes receiving a plurality of audio-video electrical signals at an optical transmitter. The optical transmitter may also receive a plurality of out-of-band electrical signals. The optical transmitter may collectively modulate the audio-video electrical signals to generate a composite electrical signal. In one aspect, the optical transmitter bias current-modulates a bias current level of the composite electrical signal using the electrical out-of-band signals, and generates a modulated electrical signal based on the bias current-modulating. The optical transmitter may convert the modulated electrical signal into a modulated optical signal using a laser diode, and transmit the modulated optical signal to an optical receiver over an optical communication channel.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Systems and methods for HDMI signal communication over an optical communication link are described. One aspect includes receiving an HDMI control signal from an HDMI master device, and another HDMI control signal from an HDMI sink terminal via a communication resources. The method identifies half-duplex communication resource contention between the HDMI control signal and the other HDMI control signal, and transitions a communication direction of the half-duplex communication resources to give the HDMI control signal precedence over the other HDMI control signal. Subsequent to transitioning the communication direction, the method transfers the HDMI control signal to the HDMI sink terminal via the communication resources. Subsequent to transferring the HDMI control signal, the method again transitions the direction of the half-duplex communication resources, and transfers the other HMDI control signal to the HDMI master device.

Abstract: Dynamically-switchable optical cables are described. One aspect includes a first terminal and a second terminal, each including an HDMI high-speed electrical interface. Each terminal may include a hot-plug signal analysis unit configured to receive one or more HDMI hot-plug detect signals, analyze the HDMI hot-plug detect signals, and determine if the associated terminal is connected to one of an HDMI signal source or an HDMI signal sink. Each terminal may include a signal transmitting unit electrically connected to the respective HDMI high-speed electrical interface, and a signal receiving unit electrically connected to the respective HDMI high-speed electrical interface. The optical cable may include a first optical communication channel connecting an output of the first signal transmitting unit to an input of the second signal receiving unit, and a second optical communication channel connecting an output of the second signal transmitting unit to an input of the first signal receiving unit.

Abstract: Dynamically-switchable optical cables are described. One aspect includes a first terminal and a second terminal, each including a USB/Thunderbolt high-speed electrical interface. Each terminal may include a USB/Thunderbolt signal analysis unit configured to receive one or more USB/Thunderbolt low-speed signals, analyze the USB/Thunderbolt low-speed signals, and determine if the associated terminal is connected to one of a USB/Thunderbolt signal source or a USB/Thunderbolt signal sink. Each terminal may include a signal transmitting unit electrically connected to the respective USB/Thunderbolt high-speed electrical interface, and a signal receiving unit electrically connected to the respective USB/Thunderbolt high-speed electrical interface.

Abstract: Systems and methods that implement dynamically-switchable optical cables are described. One method includes a first terminal receiving one or more transmit high-speed electrical signals and one or more first low-speed electrical signals by a first terminal from a communication signal source. The first terminal may perform a first analysis on the first low-speed electrical signals, and determine a transmission direction based on the first analysis. A second terminal may receive or more second low-speed electrical signals by a second terminal from a communication signal sink. The second terminal may perform a second analysis the second low-speed electrical signals, and determine a reception direction based on the second analysis. The first terminal may convert the transmit high-speed electrical signals into high-speed optical signals, and transmit the high-speed optical signals to the second terminal via an optical communication channel.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Systems and methods for signal communication over an optical link are described. One aspect includes receiving a source CONFIG1 signal from a DP master device and a sink CONFIG1 signal from a sink terminal. The source and sink CONFIG1 signals are analyzed. It is determined whether a signal transmission mode is a DP protocol. For a DP protocol, a pair of source AUX signals is received from the DP master device. A pair of sink AUX signals is received from the sink terminal. Communication resource contention between the source and sink AUX signals is identified. A communication direction of the communication resources is transitioned to give the source AUX signals precedence over the sink AUX signals. The source AUX signals are transferred to the sink terminal via the communication resources. The direction of the communication resources is again transitioned. The sink AUX signals are transferred to the DP master device.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.